Methods of treatment using orodispersible desmopressin pharmaceutical formulations
Described herein are methods of treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, by administering desmopressin acetate in an orodispersiblc solid dosage form that disintegrates in the mouth within 10 seconds and includes an amount of desmopressin acetate, measured as the free base, of from 10 to 600 μg.
1. A method of treating a disease or condition selected from the group consisting of incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, comprising administering to a subject an effective and generally non-toxic amount of desmopressin acetate in an orodispersible solid dosage form, wherein said dosage form (A) disintegrates in the mouth within 10 seconds and (B) comprises an amount of desmopressin acetate, measured as the free base, of from 10 to 600 μg.
2. The method of claim 1 , wherein the disease or condition is primary nocturnal enuresis (PNE).
3. The method of claim 1 , wherein the disease or condition is nocturia.
4. The method of claim 1 , wherein the dosage form comprises an open matrix network carrying the desmopressin acetate, the open matrix network being comprised of a water-soluble or water-dispersable carrier material that is inert towards desmopressin.
5. The method of claim 4 , wherein the open matrix network comprises gelatin.
6. The method of claim 5 , wherein the gelatin is fish gelatin.
7. The method of claim 6 , wherein the fish gelatin is non-gelling.
8. The method of claim 1 , wherein the dosage form disintegrates in the mouth within 5 seconds.
9. The method of claim 1 , wherein the dosage form disintegrates in the mouth within 2 seconds.
10. The method of claim 1 , wherein the dosage form disintegrates in the mouth within 1 second.
11. The method of claim 1 , wherein the dosage form is administered once per day.
12. The method of claim 1 , wherein the dosage form is administered twice per day.
13. The method of claim 1 , wherein the method achieves a maximum plasma concentration of desmopressin in about 0.5-2 hours after administration.
14. The method of claim 1 , wherein the method achieves a mean elimination half-life of desmopressin of about 2.8-3 hours after the maximum plasma concentration is reached.
15. The method of claim 1 , wherein the method achieves a linear pharmacokinetics of desmopressin.